GLP-1 drugs reduced obesity-related cancer and death rates versus DPP-4s with no increased cancer risk, a large real-world study shows. In an assessment of more than 170,000 patients, GLP-1 drugs were not linked with higher cancer rates, and led to […]
GLP-1 Drugs Linked to Fewer Obesity-Related Cancers Read More »
Results were consistent with research in advanced renal cell carcinoma treated with Cabometyx, Opdivo and Yervoy: © SciePro – stock.adobe.com. Patients with advanced renal cell carcinoma experienced a continued benefit in progression-free survival (PFS) after 45 months when treated with
Cabometyx Combo Maintains Progression-Free Survival Benefit in Advanced RCC Read More »
Zejula-Jemperli Shows Promising Responses in Breast Cancer A small cohort of patients with germline BRCA-mutated estrogen receptor (ER)-positive, HER2-negative breast cancer demonstrated responses after receiving a combination of neoadjuvant Zejula (niraparib) plus Jemperli (dostarlimab-gxly), according to data from group C
Zejula-Jemperli Combo Shows Promising Responses in Breast Cancer Subset Read More »
Venclexta-based regimen improved response rates in patients with acute myeloid leukemia and myelodysplastic syndromes, study results demonstrated. Patients who were minimal residual disease (MRD)-negative with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) experienced improved complete response
Venclexta Plus Mavenclad Boosts Response Rates in AML, MDS Read More »
Optune, Temodar, and Keytruda may control brain tumors, as patients with glioblastoma experienced tumor control after vaccination and immunotherapy. Patients with glioblastoma, the most common malignant brain tumor, experienced tumor control after complete in-situ vaccination and anti-PD-1 immunotherapy, which resulted
Optune Plus Temodar and Keytruda May Result in Brain Tumor Control Read More »
A first-line treatment combination of Jemperli (dostarlimab-gxly) and chemotherapy demonstrated better effectiveness in patients with advanced non-small cell lung cancer (NSCLC) versus first-line treatment with Keytruda (pembrolizumab) plus chemotherapy. Findings, demonstrated by the phase 2 PERLA trial, were presented at
Jemperli-Chemo Regimen Shows Survival Promise in Advanced NSCLC Read More »
Patients with mismatch repair proficient (pMMR) locally advanced rectal cancer who underwent non-operative management of their disease did not experience an impact in distance relapse-free survival (the time when a patient survives without signs of that cancer; DRFS) when undergoing
Non-Surgical Options May Maintain Relapse-Free Survival in Rectal Cancer Subset Read More »
